Uncontrolled intravenous pilot in two previous users
How the study was set up
Two adults who had previously received intravenous BPC-157 were observed during a short pilot with baseline and follow-up testing.
What the researchers measured
Vital signs, reported adverse effects, and blood markers concerning liver, kidney, thyroid, glucose, and other functions were checked over several days.
How to read this evidence
Researchers observed people or measured naturally occurring peptide levels. Associations do not show that administering the peptide caused a benefit.
Results in context
The authors reported no measured changes of concern in these two participants. This very small, short observation cannot establish general safety, detect uncommon events, or describe long-term effects.
What this does not establish
Two selected previous users and only three days of follow-up cannot establish safety, detect uncommon harms, or support other routes of administration.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.
Publication indexing
Journal Article
Indexed subjects
Humans · Pilot Projects · Male · Female · Infusions, Intravenous · Middle Aged · Aged · Peptide Fragments
Source checked
October 4, 2026. Years follow journal issues; online-first dates may differ.